17α-Methylprogesterone (original) (raw)
17α-Methylprogesterone (17α-MP), or 17α-methylpregn-4-ene-3,20-dione, is a steroidal progestin related to progesterone that was synthesized and characterized in 1949 but was never marketed. Along with ethisterone (1938) and 19-norprogesterone (1951), 17α-MP was one of the earliest derivatives of progesterone to be identified as possessing progestogenic activity. Similarly to progesterone and derivatives like 17α-hydroxyprogesterone and 19-norprogesterone, 17α-MP was found to possess poor (though not negligible) oral bioavailability, but showed improved progestogenic activity relative to progesterone when administered via other routes (e.g., subcutaneous or vaginal). In addition to its activity as a progestogen, 17α-MP has also been found to possess some antiglucocorticoid activity.
| Property | Value |
|---|---|
| dbo:abstract | 17α-Methylprogesterone (17α-MP), or 17α-methylpregn-4-ene-3,20-dione, is a steroidal progestin related to progesterone that was synthesized and characterized in 1949 but was never marketed. Along with ethisterone (1938) and 19-norprogesterone (1951), 17α-MP was one of the earliest derivatives of progesterone to be identified as possessing progestogenic activity. Similarly to progesterone and derivatives like 17α-hydroxyprogesterone and 19-norprogesterone, 17α-MP was found to possess poor (though not negligible) oral bioavailability, but showed improved progestogenic activity relative to progesterone when administered via other routes (e.g., subcutaneous or vaginal). In addition to its activity as a progestogen, 17α-MP has also been found to possess some antiglucocorticoid activity. The observation of two-fold improved potency of 17α-MP relative to progesterone led to renewed interest in 17α-substituted derivatives of progesterone. Subsequently, hydroxyprogesterone acetate and hydroxyprogesterone caproate were synthesized in 1953 and introduced in 1956 and 1957, respectively, and medroxyprogesterone acetate was discovered in 1957 and introduced in 1959. In addition, though 17α-MP itself was never introduced for medical use, progestogen derivatives of the compound, including medrogestone (1966) and the 19-norprogesterone derivatives demegestone (1974), promegestone (1983), and trimegestone (2001), have been marketed. (en) |
| dbo:casNumber | 1046-28-2 |
| dbo:class | dbr:Progestin dbr:Progestogen |
| dbo:fdaUniiCode | TYW2G0D7NC |
| dbo:pubchem | 101951 |
| dbo:thumbnail | wiki-commons:Special:FilePath/Methylprogesterone.svg?width=300 |
| dbo:wikiPageID | 51567463 (xsd:integer) |
| dbo:wikiPageLength | 8192 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID | 1115648707 (xsd:integer) |
| dbo:wikiPageWikiLink | dbr:Progesterone dbr:Progestin dbr:Promegestone dbr:Methylestradiol dbr:Progestogen dbr:19-norprogesterone dbr:Demegestone dbr:Antiglucocorticoid dbr:Hydroxyprogesterone_caproate dbr:Intravaginal_administration dbr:17α-Bromoprogesterone dbc:Diketones dbc:Pregnanes dbc:Progestogens dbr:Medrogestone dbr:Medroxyprogesterone_acetate dbr:Chemical_synthesis dbr:Oral_administration dbc:Antiglucocorticoids dbr:Steroid dbr:Subcutaneous_injection dbr:Trimegestone dbr:Ethinylestradiol dbr:Ethisterone dbr:Hydroxyprogesterone_acetate dbr:Bioavailability dbr:Methyltestosterone dbr:17α-hydroxyprogesterone |
| dbp:c | 22 (xsd:integer) |
| dbp:casNumber | 1046 (xsd:integer) |
| dbp:chemspiderid | 92105 (xsd:integer) |
| dbp:class | dbr:Progestin dbr:Progestogen |
| dbp:h | 32 (xsd:integer) |
| dbp:iupacName | -17 (xsd:integer) |
| dbp:o | 2 (xsd:integer) |
| dbp:pubchem | 101951 (xsd:integer) |
| dbp:smiles | CCC1C (en) |
| dbp:stdinchi | 1 (xsd:integer) |
| dbp:stdinchikey | UFIQEZHBGZCWRS-QZKGNRECSA-N (en) |
| dbp:synonyms | 17 (xsd:integer) |
| dbp:unii | TYW2G0D7NC (en) |
| dbp:width | 225 (xsd:integer) |
| dbp:wikiPageUsesTemplate | dbt:Drugbox dbt:Glucocorticoid_receptor_modulators dbt:Progesterone_receptor_modulators dbt:Reflist dbt:See_also dbt:Short_description dbt:Cascite dbt:Fdacite |
| dct:subject | dbc:Diketones dbc:Pregnanes dbc:Progestogens dbc:Antiglucocorticoids |
| rdf:type | owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:Drug |
| rdfs:comment | 17α-Methylprogesterone (17α-MP), or 17α-methylpregn-4-ene-3,20-dione, is a steroidal progestin related to progesterone that was synthesized and characterized in 1949 but was never marketed. Along with ethisterone (1938) and 19-norprogesterone (1951), 17α-MP was one of the earliest derivatives of progesterone to be identified as possessing progestogenic activity. Similarly to progesterone and derivatives like 17α-hydroxyprogesterone and 19-norprogesterone, 17α-MP was found to possess poor (though not negligible) oral bioavailability, but showed improved progestogenic activity relative to progesterone when administered via other routes (e.g., subcutaneous or vaginal). In addition to its activity as a progestogen, 17α-MP has also been found to possess some antiglucocorticoid activity. (en) |
| rdfs:label | 17α-Methylprogesterone (en) |
| rdfs:seeAlso | dbr:List_of_progestogens |
| owl:sameAs | wikidata:17α-Methylprogesterone https://global.dbpedia.org/id/2buM4 |
| prov:wasDerivedFrom | wikipedia-en:17α-Methylprogesterone?oldid=1115648707&ns=0 |
| foaf:depiction | wiki-commons:Special:FilePath/Methylprogesterone.svg |
| foaf:isPrimaryTopicOf | wikipedia-en:17α-Methylprogesterone |
| is dbo:wikiPageRedirects of | dbr:Methylprogesterone dbr:17-Methylprogesterone dbr:17-methylprogesterone dbr:17α-methylprogesterone |
| is dbo:wikiPageWikiLink of | dbr:Progestogen_(medication) dbr:C22H32O2 dbr:List_of_progestogens dbr:11-Dehydroprogesterone dbr:19-Norprogesterone dbr:17α-Bromoprogesterone dbr:17α-Hydroxyprogesterone dbr:Methylprogesterone dbr:17-Methylprogesterone dbr:17-methylprogesterone dbr:17α-methylprogesterone |
| is foaf:primaryTopic of | wikipedia-en:17α-Methylprogesterone |
